Vesicular glutamate transporter type 2 (VGLUT2) is known to play an important role in 3 mediating the heat hyperalgesia induced by inflammation. However, the underlying 4 mechanism for this activity is poorly understood. Cyclin-dependent kinase 5 (Cdk5), serving 5 as a key regulator in mediating release of glutamate, contributed to the inflammatory heat . It 6 remains unknown whether there is a bridge between Cdk5 and VGLUT2 for mediating 7 inflammatory pain. Therefore, we designed the experiment to determine whether VGLUT2 8 signaling pathway is involved in Inflammatory pain mediated by Cdk5 and the heat 9 hyperalgesia induced by complete Freund's adjuvant (CFA) can be reversed by roscovitine, a 10 selective inhibitor for Cdk5 through inhibition of VGLUT2 expression. 11 Immunohistochemistry results suggest that when compared with rats in a control group, rats 12 in an experimental group showed significant coexpression of Cdk5/VGLUT2 in small and 13 medium-sized neuronal cells of the dorsal root ganglion (DRG) and spinal cord between days 14 1 and 3 following subcutaneous injection of CFA. Moreover, our study revealed that the 15 expression of VGLUT2 protein in DRG and spinal cord was remarkably increased between 16 days 1 and 3 following CFA injection. Additionally, p25 but not p35, a activator of 17 Cdk5,protein was significantly increased and reduced by roscovitine.The increased 18 expressions of VGLUT2 protein was significantly reduced by roscovitine as well. Our study 19 showed that VGLUT2/Cdk5 signaling pathway contributed to the inflammatory pain 20 medicated by Cdk5/p25. 21 22
Introduction 23 Pain caused by inflammation in the peripheral or central nervous system remains a 24 significant clinical problem, and is often resistant to treatment with conventional analgesics. 25 Glutamate is the major excitatory neurotransmitter in the central nervous system (CNS) and 26 plays a key role in processing of nociceptive pain [1] . Prior to its release from excitatory 27 synapses, glutamate is transported into synaptic vessels by vesicular glutamate transporters 28 (VGLUTs) composed of VGULT proteins 1-3. Previous studies have established that 29 VGLUT1, 2, and 3 proteins are expressed by largely non-overlapping and functionally 30 distinct populations of glutamatergic neurons, and play multiple roles in the CNS [2] [3] [4] . 3 1 However, only VGLUT 2 plays a key role in mediating pain hypersensitivity induced by 2 inflammation and peripheral nerve injury [5] [6] [7] [8] [9] [10] [11] [12] . Co-expression of VGLUT2 and two main 3 nociceptors of calcitonin gene related peptide (CGRP) and transient receptor potential channel 4 (TRPV1) was observed in small and medium-sized neurons of the dorsal root ganglion (DRG) 5 in mice [6, 7] . Additionally, VGLUT2 knock-out mice challenged with CFA demonstrate a 6 complete loss of heat hyperalgesia, whereas CFA-induced mechanical hypersensitivity 7 remains intact. Nevertheless, a detailed mechanism for VGLUT2 mediation of 8 inflammation-induced heat hyperalgesia remains elusive. 9 Emerging evidence suggests that the serine/threonine kinase Cdk5 plays an important role 10 in mediating inflammation-induced heat hyperalgesia [13] [14] [15] [16] . A previous study showed that 11 Cdk5 can modulate CFA-induced heat hyperalgesia by controlling membrane trafficking of 12 TRPV1 and phosphorylating vanilloid receptor 1 (VR1) in the dorsal root ganglion (DRG) of 13 rats [14, 15] . The activities of Cdk5 and p35 in the spinal cord were significantly increased 14 following peripheral injection of CFA. Furthermore, both Cdk5 kinase activity and heat 15 hyperalgesia were inhibited by Cdk5/p35 knockdown or intrathecal administration of 16 roscovitine. Previous studies have suggested that presynaptic Cdk5 is the primary regulator of 17 neurotransmitter release in the CNS [17] . Synapsin II is a synaptic vesicle protein associated 18 with the release of neurotransmitters, and a recent study revealed that expression of both 19 VGLUT1 and VGLUT2 was strongly reduced in the spinal cord of synapsin II knockout mice 20 [18]. Moreover, our previous studies revealed that increased levels of synaptophysin protein, 21 an important presynaptic vesicle membrane protein that functions in release of 22 neurotransmitters, are involved in mediating CFA-induced heat hyperalgesia mediated by 23 Cdk5 in rats. Furthermore, the recent study showed that VGLUT2-pH fluorescence 24 co-localizes with synaptophysin at synaptic boutons and was invovled in the trafficking of 25 synaptic vesicles [19] . This suggests that Cdk5 may mediate inflammation-induced heat 26 hyperalgesia by controlling the release of neurotransmitters [20] . Here, we report that the 27 VGLUT2/Cdk5 signaling pathway contributed to the inflammatory pain medicated by Cdk5. paws of rats respectively. The saline group was settled as a control (n = 6/group). The same 9 volume of saline as used for control group was injected into ipsilateral and contralateral paws 10 of rats in the control group (n = 6/group).
11
Surgery and drug administration 12 Drugs used in this study were intrathecal injection as described before, with a slight 13 modification [22] . Briefly, a catheter (PE-10: 0.28 mm i.d. and 0.61 mm o.d.; Clay Adams, 14 Parsippany, NJ, USA) was inserted at the lumbar level of the spinal cord between lumbar 15 vertebrates 4 and 5 (L4 and L5) of the rats which were anesthetized before with the 4% 16 pentobarbital (40 mg/kg). 5 µL of 2% lidocaine was confirmed to be injected through the 17 catheter for the recovery after the anesthesia and surgery, followed by flushing with 15 µL of 18 saline. Following this procedure, successful insertion of the catheter was further confirmed if 19 the animal presented with impaired motor function of their hind legs at 10 s post-lidocaine 20 administrations. Following surgery, 5 µL of roscovitine (100 µg) (Sigma, St. Louis, MO, 21 USA R7772) dissolved in 10% DMSO was delivered for 5 consecutive days to the rats in the 22 experimental group, followed by rinsing of 15 µL of sterile saline 0.5 h before a single 23 treatment with CFA (n = 6/group). The same concentration of roscovitine and DMSO was 24 injected into the rats in the vehicle control group (n = 6) and the experimental group. 25 Behavioral test 26 Heat hyperalgesia was quantified by measuring paw withdrawal latencies (PWL) in 27 response to radiant heat stimulation as previously described [23] . Briefly, radiant heat was 28 directed to the plantar surface of each hind paw through a 1 mm thick glass plate. In order to 29 prevent tissue damage, a 20 second cut-off limit was radicate for heat exposure. The time 30 between the onset of the heat stimulus and a manifestation of paw withdrawal response was 5 1 recorded as the thermal nociceptive latency period. Rats were allowed to adapt to the room 2 for 30 min before the behavioral test. The thermal stimulus was then delivered to the 3 ipsilateral and contralateral hind-paws of rats in both groups after adaption. The time of PWL 4 measurements was at 0 d, 6h, 1 d, 3 d, and 5 d post-CFA or saline injection, which was 5 recorded as the average result of 3 trials for each hind paw. The interval time between PWL 6 measurements taken with the ipsilateral and contralateral paws was 5 minutes. So, again PWL 7 measurements of the rats in the DMSO and roscovitine-pretreatment groups were taken by the 8 same method.The behavioral results showed that the heat hyperalgesia induced by CFA 9 significantly decreased from 6h to 5 d and reversed by roscovitine ,which is in accordance 10 with our previous studies [21]. The effects of roscovitine on heat hyperalgesia induced by injection of CFA into the 2 ipsilateral hind paws of rats was determined by measuring heat hyperalgesia on days 1-5 3 following CFA injection. Compared to the contralateral hind paw of animals in the same 4 group during the same time span, the average thermal PWL threshold (seconds) of the 5 ipsilateral hind paw was significantly reduced 6 hours and on days 1-5 following CFA 6 injection (**P < 0.01, Figure 1 A, n = 6/group). However, no pronounced difference was 7 observed between the ipsilateral and contralateral paws of rat in the control group (P > 0.05, 8 Figure 1B , n = 6/group). Furthermore, on days 1 and 3 after CFA injection, the average PWL 9 thresholds of isolateral paws pretreated with roscovitine for 30 min prior to intraplantar CFA 10 injection were remarkably increased, when compared to the ipsilateral paws of animals 11 pretreated with DMSO (**P < 0.01, Figure 1 B, n = 6/group). 12 13 To investigate the possible morphologic relationships between Cdk5 and VGLUT2,light 14 microscopy examinations of the DRG from the L4-L6 segments of spinal cord was to 15 illustrate a dense plexus of immunoreactive elements in the small and medium diameter Increased VGLUT2 protein expression in DRG was significantly reduced by roscovitine 28 We next used western blot analysis to investigateVGLUT2 protein expression in DRG To varify the role of p25 or p35 as a activator of Cdk5 in mediating the heat hyperalgesia by 12 CFA, the p25and p35 protein from the L4-L6 ipsilateral spinal cord neurons were 13 exiamed,respectively. p25 protein from the L4-L6 ipsilateral spinal cord neurons challenged 14 with CFA was significantly increased on days 1 and 3 as comapred with the control group. 15 However, p35 remians markedly unchanged as compared with the control group. (Figure 6 16 **P < 0.01, n = 4/group) 17 Heat hyperalgesia was significantly inhibited by roscovitine via p25 rather than p35 18 To explore the pathway inhibiting heat hyperalgesia by roscovitine, we respectively detected 19 the protein changing of The present study preliminary illustrated that the VGLUT2 signaling pathway was involved 26 in CFA-induced heat hyperalgesia mediated by Cdk5 in the DRG and spinal cord neurons. It 27 is well established that glutamate is the major excitatory neurotransmitter in the CNS, and 28 plays a key role in nociceptive processing in inflammatory and neuropathological pain [1] . 15 recent study further indicated that VGLUT2 was invovled in the trafficking of synaptic 16 vesicles by interacting with synaptophysin at synaptic boutons [19] , which further show that 17 VGLUT2 mediates the heat hyperalgesia via Cdk5 pathway. In addition, another study made 18 it clear that the expression of VGLUT1 and VGLUT2 gene was strongly reduced in synapsin 19 II (another key vesicle protein involved in release of neurotransmitters) knockout mice [18] . 20 Thus, we examined the possible linkage between Cdk5 and VGLUT2 in mediating heat 21 hyperalgesia induced by CFA using our current model. 22 In our research, the immunohistochemistry results showed that the co-expression of Cdk5 Cdk5 and VGLUT2 was found to be significantly increased between days 1 and 3 following 1 plantar injection of CFA, as compared with the control group of rats that was challenged with 2 saline. The increased co-expression of Cdk5 and VGLUT2 lasted for more than 3 days, until 3 day 5, which suggests a key role of these molecular factors in the induction stage of chronic 4 inflammatory pain. Subsequently, our study explored the effects of Cdk5 on VGLUT2 by 5 administering roscovitine via intrathecal injection on day 1 and day 5 prior to CFA injection, 6 which allowed us to observe the changes in protein of VGLUT2 under the heat hyperalgesia 7 condition. 8 Previous studies conducted using a CFA-induced inflammatory pain model demonstrated 9 that thresholds of heat hyperalgesia in mice with VGLUT2 knockout in the DRG were 10 significantly increased compared to thresholds in wild-type mice, suggesting that VGLUT2 11 plays a key role in mediating the heat hyperalgesia induced by peripheral injection of CFA. In 12 our study, both VGLUT2 and Cdk5 expression in the DRG and spinal cord were significantly 13 increased between days 1 and 3 following CFA injection, and returned to baseline levels on 14 day 5. In the current study, an intrathecal injection of roscovitine was used to determine 15 whether endogenous VGLUT2 was inhibited by roscovitine in DRG and spinal cord neurons. 16 The results showed that increased VGLUT2 protein expressions were significantly reduced by 17 roscovitine. protein was significantly reduced by intrathecal injection of roscovitine between day 1 and 2 day 3.Data shown represent the Ave ± SEM, *P < 0.05 n = 3/group (B).
Upregulated expression of Cdk5/VGLUT2 in DRG neurons
3 Figure 6 . p25 but not p35 was markedly increased in the spianl cord 4 Compared with the control group, p25 expression was significantly increased from day 1 5 following intraplantar injection of CFA. However, p35 expression was not significantly 6 increased day 1 as compared with the control group. *P < 0.05 n = 3/group . 7 Figure 7 . Heat hyperalgesia was significantly inhibited by roscovitine via p25 rather than p35 8 Compared to DMSO-treated controls, the increased expression of p25 protein was 9 significantly reduced by intrathecal injection of roscovitine between day 1. However, the 10 effects of administration of on p35 protein expression. Data shown represent the Ave ± 11 SEM,*P < 0.05 n = 3/group (B). 
